Department of Medical Genetics, Samsun Training and Research Hospital, Samsun, Turkey.
Department of Medical Genetics, Intergen Genetic Centre, Ankara, Turkey.
Endocr Metab Immune Disord Drug Targets. 2021;21(2):324-337. doi: 10.2174/1871530320666200708135826.
Fabry Disease (FD, OMIM#301500) is a progressive, life-threatening, multisystemic, rare lysosomal storage disease. Today, approximately 1000 mutations are recorded in the Human Gene Mutation Database (www.hgmd.org) for GLA. Among the identified mutations, genetic variants of unknown significance (GVUS) and novel mutations cause problems in terms of diagnosis and treatment approach.
In our study, 510 high-risk patients were enrolled. 229 out of 510 were Male (45%) (Mean age was 40.8 ±15.0) and 281 of were Female (55%) (Mean age was 39, 7±15.5). The definite diagnosis of the FD was confirmed by GLA gene sequence analysis. GLA mutation was found in 15 cases (3.4%). Family members of the relevant indexes were included in the screening programs according to the X-linked inheritance pattern. And then we conducted family screening on 74 family members of 15 index cases. Of those 74 cases, 39 had mutations (53%). In males, α-GalA activity and in both gender Lyso-Gb3 levels were measured and multisystem evaluation was performed in all cases with the mutation.
We found six different familial mutation types; two of them pathogenic; p.D170N (1), p.P205S (13), one of them GVUS; p.Q330R (1), three of them likely benign; p.D313Y (12), p.S126G (25), c.-30G>A (2) mutations were detected.
The purpose of this retrospective study is to approach Fabry disease on a genetic basis and to improve its management and to draw attention to the importance of early diagnosis. We also aimed to evaluate the appropriate algorithms to determine whether the mutation is the FD-causing mutation or not.
法布瑞氏病(FD,OMIM#301500)是一种进行性、危及生命、多系统的罕见溶酶体贮积病。目前,在人类基因突变数据库(www.hgmd.org)中已记录了大约 1000 个 GLA 基因突变。在所鉴定的突变中,遗传变异的意义不明(GVUS)和新突变在诊断和治疗方法方面造成了问题。
在我们的研究中,共纳入了 510 名高危患者。其中 229 名(45%)为男性(平均年龄为 40.8±15.0),281 名为女性(55%)(平均年龄为 39.7±15.5)。FD 的明确诊断通过 GLA 基因序列分析得到确认。在 15 例(3.4%)中发现了 GLA 突变。根据 X 连锁遗传模式,纳入了相关指标的家庭成员进行筛查计划。然后,我们对 15 例指数病例的 74 名家庭成员进行了家系筛查。在这 74 例中,有 39 例发生了突变(53%)。在男性中,测量了α-半乳糖苷酶 A 活性,在所有有突变的病例中都进行了多系统评估。
我们发现了六种不同的家族性突变类型;其中两种为致病性的;p.D170N(1),p.P205S(13),一种为意义不明的突变;p.Q330R(1),三种可能为良性的突变;p.D313Y(12),p.S126G(25),c.-30G>A(2)突变。
本回顾性研究的目的是从遗传基础上研究法布瑞氏病,以改善其管理,并引起人们对早期诊断的重视。我们还旨在评估确定突变是否为 FD 致病突变的适当算法。